ShigActive

AXP000226.1 · Phage therapy

Platform
phage cocktail (non-engineered)
Originator
Intralytix
Sponsor
Intralytix

Names

NameTypeSource
ShigActivepreferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Shigella bacteriophage (cocktail)
Replication
replicating
Route
oral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05182749Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of ShigellosisActive not recruitingPhase 1/22023-02-232024-12-0952Shigellosis

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 39335031Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial.Antibiotics (Basel, Switzerland)2024name in title: ShigActive
PMID 26909243Bacteriophage administration significantly reduces Shigella colonization and shedding by Shigella-challenged mice without deleterious side effects and distortions in the gut microbiota.Bacteriophage2015name in abstract: ShigActive

NIH grants

ProjectTitleOrganisationPIYearsLinked by
U01AI148054Bacteriophage-based approach for managing Shigella infectionsINTRALYTIX, INC.SULAKVELIDZE, ALEXANDER2020–2024name in abstract: ShigActive

Notes

Oral phage preparation against Shigella, tested in a human challenge model of shigellosis with Shigella flexneri 2a (phase 1/2a NCT05182749).

How to cite

ShigActive (AXP000226.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000226.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.